P-D-R Pharma Documentation Ring

The P-D-R is an association whose members represent the scientific information departments of the leading international R&D-based pharmaceutical corporations.

Latest News from the P-D-R Company Websites

Published 24 June 2017 | 3:58 am

Pfizer Groton Laboratories Provides Community Grants to Organizations Impacting Science and Math Education

Pfizer Groton Laboratories Provides Community Grants to Organizations Impacting Science and Math Education more ...

Published 23 June 2017 | 6:10 pm

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard more ...

Published 23 June 2017 | 5:49 pm

From nurse to patient: facing an aggressive blood cancer

After being diagnosed with an aggressive form of leukemia, Ilana Massi defied the odds with the help of her friends and family. more ...

Published 23 June 2017 | 2:00 pm

Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer

CHMP positive recommendation is based on Phase III data demonstrating a 20% reduction in risk of disease worsening or death over anastrozole more ...

Published 23 June 2017 | 1:45 pm

European CHMP Adopts Positive Opinion for Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes

- Vosevi is Gilead's Fourth Sofosbuvir-Based Treatment to Receive CHMP Positive Opinion for the Treatment of Chronic HCV Infection - more ...

Published 23 June 2017 | 11:26 am

Annual Report 2016

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO. more ...

Published 23 June 2017 | 10:52 am

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

CHMP opinion based on pivotal Phase III trial that showed Kisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone among more ...

Published 23 June 2017 | 9:35 am

Takeda Presents Data from Phase 1/2 Studies for NINLAROTM (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

- Early studies of weekly and twice-weekly ixazomib plus lenalidomide and dexamethasone demonstrate deep responses after induction, with deepening responses seen after more ...

Published 23 June 2017 | 9:01 am

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data more ...

Published 23 June 2017 | 9:01 am

Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®

New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP more ...

Pharma Documentation Ring:
25 companies - 4 common aims:

  • Promote exchange of experience/networking among members
  • Encourage commercial development of new information services and systems
  • Jointly assess new and existing products and services
  • Provide a forum for the information industry
  • How to become a P-D-R member?
Next Annual General Meeting, Berlin, September 26 – 29, 2017

Next Annual General Meeting, Berlin, September 26 – 29, 2017